Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 2009 IP Promotion Plan Calls For Patent Protection for New Dosage and Treatment Regimens
July 13, 2009
- Nissui Pharma. to Market Switch OTC Version of Epadel from Mochida
July 13, 2009
- JSGM Presents Proposals to Promote Use of Generics
July 13, 2009
- Korosho to Inspect Generics Containing 5 More APIs
July 13, 2009
- Lasting Decreases in BP Obtained with Telmisartan + Amlodipine
July 13, 2009
- Concrete Reasons for Lack of Enthusiasm about Use of Generics to Be Determined
July 13, 2009
- R&D NEWS IN BRIEF
July 13, 2009
- Biosimilars Will also Struggle in Japan: Datamonitor
July 13, 2009
- Possible Link between Lantus and Cancer Requires Further Study: EASD
July 13, 2009
- TPA Provides Generics Comparison List Online
July 13, 2009
- Clarify Causes of Gender, Ethnic Differences in Lung Cancer: Dr Kawaguchi
July 13, 2009
- Eiken Licenses LAMP Method to Toshiba
July 13, 2009
- Drug Cost Ratio Remains Virtually Flat at 29.0% in FY2008
July 13, 2009
- Research-Driven Firms Should Not Rely on Off-Patent Products: Mr Kinoshita
July 13, 2009
- TOPICS 2 articles
July 13, 2009
- Korosho to Create Prevention-Oriented Medical Safety System: Mr Mori
July 13, 2009
- Quintiles Leads Int'l Clinical Trials in Asia
July 13, 2009
- REGULATORY NEWS IN BRIEF
July 13, 2009
- Eisai Gives Up Filing Application for Pediatric Indication for Aricept
July 13, 2009
- Astellas to Fill Shortfall in Late-Stage Development with Licensing
July 13, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…